无过度嗜睡的冠状动脉疾病合并阻塞性睡眠呼吸暂停成人持续气道正压通气的心血管获益
该研究为 RICCADSA 随机对照试验的事后分析,纳入冠状动脉疾病合并阻塞性睡眠呼吸暂停(呼吸暂停低通气指数≥15 次/h)且 Epworth 嗜睡量表评分<10 的患者,CPAP 组 113 例、对照组 113 例,男性 85%,年龄 66±8 岁。主要终点为再次血运重建、心肌梗死、卒中与心血管死亡的复合终点。多变量 Cox 回归显示 CPAP 效应受基线 ΔHR 调节(交互作用 HR 0.49[95%CI 0.27–0.90],ΔHR 每增加 1 个标准差,P<0.05)。ΔHR 为均值以上 1 个标准差(10 次/min)者 CPAP 估计降低心血管风险 59%(6%–82%,P<0.05),而 ΔHR 为均值(6 次/min)者未见显著降低(16%[−53%–54%],P=0.6)。作者认为,ΔHR 可能识别从 CPAP 获得更大心血管获益的患者,但该结论来自事后分析。
要点
- 在无过度嗜睡的冠状动脉疾病合并阻塞性睡眠呼吸暂停患者中,基线 ΔHR 越高,CPAP 降低心血管复合终点风险的幅度越大(交互作用 HR 0.49[95%CI 0.27–0.90],ΔHR 每增加 1 个标准差,P<0.05)。
- ΔHR 为均值以上 1 个标准差(10 次/min)者,CPAP 估计降低心血管风险 59%(6%–82%,P<0.05)。
- ΔHR 为均值(6 次/min)者,CPAP 未见显著风险降低(16%[−53%–54%],P=0.6)。
- 该结果为 RICCADSA 随机对照试验的事后分析(CPAP 组 113 例 vs 对照组 113 例),作者认为 ΔHR 可能有助于识别更可能从 CPAP 获益的患者。
适用人群与场景
- 冠状动脉疾病合并阻塞性睡眠呼吸暂停(呼吸暂停低通气指数≥15 次/h)且 Epworth 嗜睡量表评分<10(无过度嗜睡)的成人。
- 来自 RICCADSA 随机对照试验人群:CPAP 组 113 例、对照组 113 例,男性 85%,年龄 66±8 岁(均值±标准差)。
诊断标准与关键阈值
- 阻塞性睡眠呼吸暂停定义为呼吸暂停低通气指数≥15 次/h。
- 无过度嗜睡定义为 Epworth 嗜睡量表评分<10。
- ΔHR 由基线多导睡眠监测测得;阈值包括均值 6 次/min 与均值以上 1 个标准差即 10 次/min。
研究设计与关键结果
- 研究类型:RICCADSA 随机对照试验的事后分析;样本量 CPAP 组 113 例、对照组 113 例;人群为冠状动脉疾病合并阻塞性睡眠呼吸暂停且 Epworth 嗜睡量表评分<10 的成人,男性 85%,年龄 66±8 岁。
- 主要终点为再次血运重建、心肌梗死、卒中和心血管死亡的复合终点;多变量 Cox 回归评估 ΔHR 对 CPAP 效应的调节作用(治疗×ΔHR 交互作用)。
- CPAP 相关风险降低随基线 ΔHR 升高而进行性增大(交互作用 HR 0.49[95%CI 0.27–0.90],ΔHR 每增加 1 个标准差,P<0.05)。
- ΔHR 为均值以上 1 个标准差(10 次/min)时,CPAP 估计降低心血管风险 59%(6%–82%,P<0.05)。
- ΔHR 为均值(6 次/min)时,CPAP 未见显著风险降低(16%[−53%–54%],P=0.6)。
证据类型、等级与局限
- 证据类型:随机对照试验(RICCADSA)的事后分析。
- 交互作用:HR 0.49(95%CI 0.27–0.90),ΔHR 每增加 1 个标准差,P<0.05。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在冠状动脉疾病合并阻塞性睡眠呼吸暂停且无过度嗜睡的患者中,ΔHR 可能有助于识别更可能从 CPAP 获得心血管获益的患者;ΔHR 较高者可能获益更大,ΔHR 为均值者未见显著获益。
指南或共识出处
- RICCADSA(Randomized Intervention with CPAP in CAD and OSA)随机对照试验
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Rationale: Randomized controlled trials of continuous positive airway pressure (CPAP) in patients with obstructive sleep apnea (OSA) have not demonstrated protection against adverse cardiovascular outcomes. Recently, observational studies revealed that OSA-related cardiovascular risk is concentrated in patients with an elevated pulse rate response to respiratory events (ΔHR). Objectives: Here, in this post hoc analysis of a prospective clinical trial, we test the hypothesis that a greater pretreatment ΔHR is associated with greater CPAP-related protection against adverse cardiovascular outcomes. Methods: ΔHR was measured from baseline polysomnography of the RICCADSA (Randomized Intervention with CPAP in CAD and OSA) randomized controlled trial (patients with coronary artery disease [CAD] and OSA [apnea-hypopnea index ⩾ 15 events/h] with Epworth Sleepiness Scale score < 10; nCPAP:ncontrol = 113:113; male, 85%; age, 66 ± 8 [mean ± SD] yr). The primary outcome was a composite of repeat revascularization, myocardial infarction, stroke, and cardiovascular mortality. Multivariable Cox regression assessed whether the effect of CPAP was moderated by ΔHR (treatment-by-ΔHR interaction). Measurements and Main Results: The CPAP-related reduction in risk increased progressively with increasing pretreatment ΔHR (interaction hazard ratio [95% confidence interval], 0.49 [0.27 to 0.90] per SD increase in ΔHR; P < 0.05). This means that in patients with a ΔHR of 1 SD above the mean (i.e., 10 beats/min), CPAP was estimated to reduce cardiovascular risk by 59% (6% to 82%) (P < 0.05), but no significant risk reduction was estimated in patients with a mean ΔHR (6 beats/min; CPAP risk reduction, 16% [-53% to 54%]; P = 0.6). Conclusions: The protective effect of CPAP in patients with CAD and OSA without excessive sleepiness was modified by the ΔHR. Specifically, patients with higher ΔHR exhibit greater cardiovascular benefit from CPAP therapy.
参考来源
- Azarbarzin A, Zinchuk A, Wellman A, et al. Cardiovascular Benefit of Continuous Positive Airway Pressure in Adults with Coronary Artery Disease and Obstructive Sleep Apnea without Excessive Sleepiness. Am J Respir Crit Care Med. 2022. PMID: 35579605. doi:10.1164/rccm.202111-2608OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。